SPRY Stock Analysis: Buy, Sell, or Hold?
SPRY - ARS Pharmaceuticals, Inc. Common Stock
$10.28
0.30 (3.01%)
▲
5d:
+4.79%
30d:
+24.91%
90d:
+34.03%
BUY
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 12, 2026
Get Alerted When SPRY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: SPRY shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: SPRY shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: SPRY is currently trading at $10.28, which is considered extended relative to its 30-day fair value range of $8.06 to $9.79.
Technical Outlook: Technically, SPRY is showing sideways momentum. Immediate support is located at $8.87, while resistance sits at $10.66. The stock is showing strong short-term momentum, up 3.0% recently.
Market Sentiment: SPRY has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $28.80 (+180.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, SPRY is showing sideways momentum. Immediate support is located at $8.87, while resistance sits at $10.66. The stock is showing strong short-term momentum, up 3.0% recently.
Market Sentiment: SPRY has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $28.80 (+180.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$8.06 -
$9.79
Company Quality Score
66/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range (+5.0% above its trading range)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.0%)
- BULLISH: Trading 180.2% below Wall St target ($28.80)
Trading Range Analysis
30-Day Trading Range
$8.06 -
$9.79
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$8.87
Resistance Level
$10.66
Current Trend
Sideways
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-10.74
Wall Street Target
$28.80
(+180.2%)
Revenue Growth (YoY)
184.5%
Profit Margin
-200.0%
Share & Embed Analysis
Last updated: June 24, 2026 4:00 AM ET
Data refreshes hourly during market hours. Next update: 5:00 AM
Data refreshes hourly during market hours. Next update: 5:00 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SPRY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 56 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 57 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 67 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
